CN102633883B - 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 - Google Patents
一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 Download PDFInfo
- Publication number
- CN102633883B CN102633883B CN201210043214.8A CN201210043214A CN102633883B CN 102633883 B CN102633883 B CN 102633883B CN 201210043214 A CN201210043214 A CN 201210043214A CN 102633883 B CN102633883 B CN 102633883B
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- plasmid
- seq
- carrier
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract description 35
- 108010011705 herstatin Proteins 0.000 title abstract description 11
- 102000001301 EGF receptor Human genes 0.000 title abstract description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title abstract description 7
- 108060006698 EGF receptor Proteins 0.000 title abstract description 6
- 108020001507 fusion proteins Proteins 0.000 title abstract description 5
- 102000037865 fusion proteins Human genes 0.000 title abstract description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 4
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 230000004927 fusion Effects 0.000 claims description 109
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 239000013612 plasmid Substances 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 13
- 241000701161 unidentified adenovirus Species 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000001890 transfection Methods 0.000 claims description 11
- 239000013613 expression plasmid Substances 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 230000009465 prokaryotic expression Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 6
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 28
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 28
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 28
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 28
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 15
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229940096437 Protein S Drugs 0.000 description 12
- 108010066124 Protein S Proteins 0.000 description 12
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 11
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 10
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 8
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 3
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005619 esophageal carcinoma Diseases 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000045108 human EGFR Human genes 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012807 shake-flask culturing Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01069—Protein-Npi-phosphohistidine-sugar phosphotransferase (2.7.1.69), i.e. sucrose phosphotransferase system II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210043214.8A CN102633883B (zh) | 2012-02-24 | 2012-02-24 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
PCT/CN2013/071516 WO2013123861A1 (zh) | 2012-02-24 | 2013-02-07 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210043214.8A CN102633883B (zh) | 2012-02-24 | 2012-02-24 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102633883A CN102633883A (zh) | 2012-08-15 |
CN102633883B true CN102633883B (zh) | 2014-06-25 |
Family
ID=46618471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210043214.8A Active CN102633883B (zh) | 2012-02-24 | 2012-02-24 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102633883B (zh) |
WO (1) | WO2013123861A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102633883B (zh) * | 2012-02-24 | 2014-06-25 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
CN103965362B (zh) * | 2013-02-06 | 2019-02-01 | 上海细胞治疗集团有限公司 | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 |
CN103965363B (zh) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
CN103319610B (zh) * | 2013-07-05 | 2016-01-27 | 华博生物医药技术(上海)有限公司 | 重组融合蛋白及其制法和用途 |
CN103819566B (zh) * | 2014-02-28 | 2016-08-17 | 中国人民解放军军事医学科学院生物工程研究所 | 融合蛋白vt-gl-b3及其编码基因和应用 |
EP3322297A4 (en) * | 2015-07-13 | 2019-04-17 | Sangamo Therapeutics, Inc. | RELEASE METHOD AND COMPOSITIONS FOR NUCLEASE-DERIVED GENOMINE ENGINEERING |
CN107011446B (zh) * | 2017-04-14 | 2020-06-16 | 姚宏 | 抗癌融合蛋白及其药物组合物和应用 |
CN109971720B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途 |
EP3891182A4 (en) * | 2018-12-03 | 2022-08-17 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd | RECOMBINATION PROTEIN TARGETING PD-L1 AND VEGF |
CN110627905B (zh) * | 2019-09-18 | 2021-04-27 | 中国医学科学院肿瘤医院 | 靶向vegf与egfr的双功能融合蛋白及其应用 |
CN111662391B (zh) * | 2020-07-15 | 2022-04-22 | 新乡医学院 | 双特异性融合蛋白、其编码基因以及用途 |
CN115246886A (zh) * | 2021-04-27 | 2022-10-28 | 丹生医药技术(上海)有限公司 | 一种抗egfr/vegf双功能融合蛋白及其用途 |
CN116675777A (zh) * | 2022-02-23 | 2023-09-01 | 苏州光度生物科技有限公司 | 包含补体抑制结构域的多特异性配体结合分子及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102311502A (zh) * | 2010-07-10 | 2012-01-11 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
WO2008027236A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
CN102633883B (zh) * | 2012-02-24 | 2014-06-25 | 上海白泽生物科技有限公司 | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 |
-
2012
- 2012-02-24 CN CN201210043214.8A patent/CN102633883B/zh active Active
-
2013
- 2013-02-07 WO PCT/CN2013/071516 patent/WO2013123861A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102311502A (zh) * | 2010-07-10 | 2012-01-11 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
Non-Patent Citations (2)
Title |
---|
Lara S. Shamieh等.Receptor binding specificities of Herstatin and its intron 8-encoded domain.《FEBS Letters》.2004,第568卷(第1-3期), |
Receptor binding specificities of Herstatin and its intron 8-encoded domain;Lara S. Shamieh等;《FEBS Letters》;20040524;第568卷(第1-3期);图1、第164页右栏倒数第2段 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013123861A1 (zh) | 2013-08-29 |
CN102633883A (zh) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102633883B (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
CN109096396B (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
CN105452288B (zh) | 抗人乳头瘤病毒16 e6 t细胞受体 | |
CN110818802B (zh) | 一种嵌合t细胞受体star及其应用 | |
WO2020200210A1 (zh) | 抗pd-l1/vegf双功能抗体及其用途 | |
ES2704411T3 (es) | Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas | |
CN108840923B (zh) | 一种靶向pd-l1的多肽及其应用 | |
CN114891751A (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
CN112979820B (zh) | 靶向cd123的嵌合抗原受体及含有靶向cd123嵌合抗原受体的双靶点嵌合抗原受体 | |
CN110662760A (zh) | 人甲胎蛋白特异性t细胞受体及其用途 | |
AU2012352454A1 (en) | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors | |
CN110551214A (zh) | 一种人源化抗Periostin单克隆抗体、及其制备方法和应用 | |
CN114044827B (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
CN110835374A (zh) | 抗ccr8×ctla-4双特异性抗体及其应用 | |
CN116064620A (zh) | 一种增强向肿瘤部位浸润能力的car-nk细胞制备及应用 | |
Williams et al. | Intrabody-based approaches to cancer therapy: status and prospects | |
CN104193828B (zh) | 同时阻断her2和vegfr信号通路的重组融合蛋白 | |
CN112111013A (zh) | 一种靶向claudin 18.2的通用型嵌合抗原受体T细胞、构建方法及其用途 | |
CN1948333B (zh) | 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用 | |
CN115304680B (zh) | 基于Pep42构建的双特异性细胞接合器分子的制备及其应用 | |
WO2004101777A1 (fr) | Virus recombine contenant un anticorps de therapie antitumorale intact comportant des regions humaines constantes et son utilisation | |
CN101302256B (zh) | 一种新的重组融合分子及其抗肿瘤治疗作用 | |
CN112996909B (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
CN111647074B (zh) | 一种her3二聚化界面抗原肽、重组抗原肽、编码基因及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171120 Address after: Zhang Jiang Valley No. 780 building, 201203 Shanghai city Pudong New Area Cailun Road, room 723, Zhangjiang hi tech Co-patentee after: SHANGHAI ENGINEERING RESEARCH CENTER FOR CELL THERAPY GROUP Co.,Ltd. Patentee after: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Address before: Zhang Jiang Valley No. 780 building, 201203 Shanghai city Pudong New Area Cailun Road, room 723, Zhangjiang hi tech Patentee before: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Patentee after: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Patentee after: SHANGHAI CELL THERAPY GROUP Co.,Ltd. Address before: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Patentee before: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Patentee before: SHANGHAI ENGINEERING RESEARCH CENTER FOR CELL THERAPY GROUP Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Patentee after: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Country or region after: China Patentee after: Shanghai Cell Therapy Group Co.,Ltd. Address before: Room 723, Zhangjiang Yaogu building, 780 Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai 201203 Patentee before: SHANGHAI ALLBRIGHT BIOTECH Co.,Ltd. Country or region before: China Patentee before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. |